产品
编 号：F458735
分子式：C20H14ClN3
分子量：331.8
分子式：C20H14ClN3
分子量：331.8
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 78351-75-4
产品详情
生物活性：
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect.
体内研究：
MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity.Animal Model:C57BL/6J male mice
Dosage:0.5 mg/kg, 3 mg/kg
Administration:Intraperitoneal injection, twice a day, for 15 days
Result:Alleviated the cuff-induced allodynia.
体外研究：
MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation .MY-5445 selectively reverses ABCG2-mediated multidrug resistance in ABCG2-overexpressing cells.MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2.MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis in S1-M1-80 cell.
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect.
体内研究：
MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity.Animal Model:C57BL/6J male mice
Dosage:0.5 mg/kg, 3 mg/kg
Administration:Intraperitoneal injection, twice a day, for 15 days
Result:Alleviated the cuff-induced allodynia.
体外研究：
MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation .MY-5445 selectively reverses ABCG2-mediated multidrug resistance in ABCG2-overexpressing cells.MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2.MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis in S1-M1-80 cell.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备